TNFRSF8 and hematologic disorder: At the time of this review, there are six ADCs approved by the US FDA for hematologic malignancies: gemtuzumab ozogamicin (CD33), brentuximab vedotin (CD30), inotuzumab ozogamicin (CD22), polatuzumab vedotin (CD79B), belantamab mafodotin (BCMA) and loncastuximab tesirine (CD19).